Datasheet for ABIN5954915

CD96 Protein (CD96) (AA 22-503) (His tag,AVI tag,Biotin)

1 Image

Go to Product page

Overview

Quantity:	200 µg
Target:	CD96
Protein Characteristics:	AA 22-503
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Biological Activity:	Active
Purification tag / Conjugate:	This CD96 protein is labelled with His tag,AVI tag,Biotin.

Product Details

Sequence:	AA 22-503
Specificity:	Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Purity:	>80 % as determined by SDS-PAGE.
Endotoxin Level:	Less than 1.0 EU per µg by the LAL method.

Target Details

Target:	CD96
Alternative Name:	CD96 (CD96 Products)
Background:	The progression of pancreatic cancer (PC) is significantly associated with tumor immune

Target Details

	escape, which may be associated with nature killer (NK) cell dysfunction. CD226, CD96, and TIGIT, which share the ligand CD155, play important roles in the regulation of NK cell function. The present study was conducted to investigate the roles of these molecules in NK cells from PC patients. TIGIT and CD96 together with the co-stimulatory receptor CD226 form a pathway that is analogous to the CD28/CTLA-4 pathway, in which shared ligands and differential receptor:ligand affinities fine-tune the immune response. Although the roles of TIGIT and CD96 as immune checkpoint receptors in T cell and natural killer cell biology are just beginning to be uncovered, accumulating data support the targeting of these receptors for improving anti-tumor immune responses. A clear understanding of the immune cell populations regulated by TIGIT and CD96 is key to the design of immunotherapies that target these receptors in combination with other existing immune checkpoint blockade therapies. The dysfunction of CD96 may trigger C syndrome: A syndrome characterized by trigonocephaly, severe mental retardation, hypotonia, variable cardiac defects, redundant skin, and dysmorphic facial features, including upslanted palpebral fissures, epicanthal folds, depressed nasal bridge, and low-set, posteriorly rotated ears.
Molecular Weight:	57.3 kDa
NCBI Accession:	NP_005807

Application Details

Comment:	Ready-to-use AvitagTM biotinylated protein: The product is exclusively produced using the AvitagTM technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA. This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.
Restrictions:	For Research Use only

Handling

Format:	Lyophilized

Handling

Buffer:	PBS, pH 7.4
Handling Advice:	Please avoid repeated freeze-thaw cycles.
Storage:	-20 °C

Images



SDS-PAGE

Image 1. Biotinylated Human CD96, His,Avitag on under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 80 % .